Data from GTx's enobosarm Phase IIb study on cancer to be presented at SIOG meeting

Published on October 8, 2012 at 8:13 AM · No Comments

GTx, Inc. (NASDAQ: GTXI) announced today there will be two scientific poster presentations on the effects of enobosarm, a selective androgen receptor modulator (SARM), on improving physical function and quality of life in middle aged and elderly cancer patients. The posters will be displayed on October 26th and 27th, 2012, at the 12th Meeting of the International Society of Geriatric Oncology to be held at the Manchester Central Convention Centre in Manchester, United Kingdom. Ryan P. Taylor, PhD, GTx's Associate Director of Medical Affairs, will present data from the company's Phase IIb clinical study of enobosarm, providing evidence that enobosarm may play an important role in the management of cancer patients with muscle wasting by improving physical function and quality of life, regardless of baseline weight loss or age.

The first poster presentation will present data exploring patient response to treatment by grouping subjects according to their baseline weight loss (less or greater than 5% in the 6 month period prior to randomization), and the age of the patient (above and below the median age of 66 years). Of the 159 subjects randomized into the study, 103 had physical function (by stair climb test) assessed at both baseline and following 16 weeks of treatment and 24% of these subjects had lost less than 5% of weight. Significant improvement in physical function was observed in enobosarm treated subjects, while placebo subjects failed to improve, regardless of baseline weight loss or age.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post